2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.

NCT Number	NCT04941599
Lead Sponsor	Vanderbilt University Medical Center Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Familial Hypercholesterolemia
Enrollment	72 participants
Start Date	2024-02-14
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-07